Unblinded by the light: amyloid-related imaging abnormalities in Alzheimer's clinical trials
A Gleason, S Ayton, AI Bush
European Journal of Neurology | WILEY | Published : 2020
A disease modifying therapy for Alzheimer's disease is one of the highest priorities in medicine. Dozens of amyloid-modifying trials have failed to meet primary endpoints. Aducanumab, a monoclonal anti-amyloid antibody, lowers plaque burden. Early findings suggested a slowing of cognitive deterioration(1). However, phase 3 trials of aducanumab were ceased in March 2019 based on a futility analysis.